An independent second opinion, built from inside the science.
Biotechnology investing sits at an unusual intersection: the science is genuinely novel, the regulatory record is still being written, and the people best positioned to evaluate both are rarely the people advising capital allocators. Polovina Scientific Advisory exists to close that gap.
Why this exists
Most diligence available to investors in this space is either written for scientists, or written by people without the scientific and regulatory background to know which risks actually matter. Polovina Scientific Advisory was built to sit in between — translating frontier biology and regulatory nuance into a read a generalist investment committee can act on.
[Add a paragraph here on the founding story — what prompted you to start this firm, and any specific experience or background worth highlighting to investors.]
Our values
We don't take board seats, advisory equity, or stakes in companies we cover. Our assessment is built solely on the science and the data in front of us.
Every read is grounded in mechanism, regulatory precedent, and what agencies have actually required of comparable programs — not press-release optimism.
An investment committee shouldn't need a PhD to use our findings. We translate the science into clear, decision-ready language without losing what matters.
Biotechnology carries real scientific and regulatory uncertainty. We say so plainly — even when it complicates the thesis.
Founder & Principal
Elias Polovina founded Polovina Scientific Advisory to give investors an independent, science-first read on biotechnology assets — the kind of scrutiny typically reserved for a company's own scientific advisors, made available to the people deciding whether to back it.
[Add background here: relevant prior roles, institutions, scientific or regulatory experience, and years of focus on biotechnology — written for an investor audience.]